title: Comparative genomic hybridization of esophageal squamous cell carcinoma: correlations between chromosomal aberrations and disease progression/prognosis.
abstract: BACKGROUND
  Esophageal carcinoma is a major cause of cancer-related deaths among males in Taiwan. However, to date, the genetic alterations that accompany this lethal disease are not understood.
  
  
  METHODS
  Chromosomal aberrations of 46 samples of esophageal squamous cell carcinoma (EC-SCC) were analyzed by comparative genomic hybridization (CGH), and their correlations with pathologic staging and prognosis were analyzed statistically.
  
  
  RESULTS
  In total, 321 gains and 252 losses were found in 46 tumor samples; thus, the average gains and losses per patient were 6.98 and 5.47, respectively. Frequent gain abnormalities were found on chromosome arms 1q, 2q, 3q, 5p, 7p, 7q, 8q, 11q, 12p, 12q, 14q, 17q, 20q, and Xq. Frequent deletions were found on chromosome arms 1p, 3p, 4p, 5q, 8p, 9p, 9q, 11q, 13q, 16p, 17p, 18q, 19p, and 19q. It was found that deletions of 4p and 13q12-q14 and gain of 5p were significantly correlated with pathologic staging. Losses of 8p22-pter and 9p also were found more frequently in patients with advanced disease. Gain of 8q24-qter was seen more frequently in patients with Grade 3 tumors. A univariate analysis found that pathologic staging; gains of 5p and 7q; and deletions of 4p, 9p, and 11q were significant prognostic factors. However, pathologic staging became the only significant factor in a multivariate analysis.
  
  
  CONCLUSIONS
  CGH not only revealed novel chromosomal aberrations in EC-SCC, but also found possible genotypic changes associated with disease progression. Despite all of the possible associations of chromosomal aberrations with disease progression, the most important prognostic factor for patients with EC-SCC was pathologic staging.
authors.affiliation: Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.
authors.forename: C C
authors.initials: CC
authors.lastname: Yen
authors.forename: Y J
authors.initials: YJ
authors.lastname: Chen
authors.forename: J T
authors.initials: JT
authors.lastname: Chen
authors.forename: J Y
authors.initials: JY
authors.lastname: Hsia
authors.forename: P M
authors.initials: PM
authors.lastname: Chen
authors.forename: J H
authors.initials: JH
authors.lastname: Liu
authors.forename: F S
authors.initials: FS
authors.lastname: Fan
authors.forename: T J
authors.initials: TJ
authors.lastname: Chiou
authors.forename: W S
authors.initials: WS
authors.lastname: Wang
authors.forename: C H
authors.initials: CH
authors.lastname: Lin
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality; D002869:Chromosome Aberrations; D015342:DNA Probes; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D013223:Statistics as Topic; D016019:Survival Analysis
chemical_list: D015342:DNA Probes